Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
Date:2/14/2008

- Second Quarter Revenue Increased 69.8% to $7.7 million

- Gross Margins Increased from 37% to 41%

- Second Quarter Net Income Increased 67.5% to $1.7 million - First Six Months Revenues Increased 82% to $14.9 million and Net Income

Increased 65% to $3.2 million for the Same Period - Growth Driven by New Distribution Partners and Increased Demand for

Products

CHENGDU, China, Feb. 14 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Inc., (OTC Bulletin Board: VSCO), a manufacturer and supplier of modernized traditional Chinese medicine (TCM) based in Chengdu, China, today announced fiscal results for its second quarter ending December 31, 2007.

Total revenue for the second quarter of 2008 increased 69.8% to approximately $7.7 million compared to approximately $4.3 million for the second quarter of 2007. Cost of goods sold for the second quarter of 2008 was approximately $4.6 million, yielding a gross profit of approximately $3.2 million and gross margins of 41%, compared to approximately $1.6 million in gross profit at a gross margin of 37.2% during the second quarter of 2007.

Operating income for the second quarter of 2008 totaled approximately $2 million, representing a 68% increase from the $1.2 million reported for the second quarter of 2007 and was directly related to the increase in revenues. Operating margins were 25.5% and 27.1% for the second quarter of 2008 and 2007, respectively.

For the second quarter of 2008, net income was approximately $1.7 million, an increase of 67.5% from $986,317 recorded during the second quarter of 2007. The Company incurred taxes of $300,000 and $160,000 for the second quarter of 2008 and 2007, respectively, which equated to an effective tax rate of 15% and 13.6%. Tianyin had 14.6 million shares outstanding on February 12, 2008.

Tianyin has experienced significant growth over the previous per
'/>"/>

SOURCE Tianyin Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 ... announced that a team from Iowa State University won ... design contest. Using a Convey HC-2ex, the team’s solution ... 14 times faster than the second place finisher. , ... world embarked upon the month long challenge, using a ...
(Date:10/20/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four ... million and provides a good start to Q4.  The orders are ... and one in the Middle East . ... said Peter Bruijns , President & CEO. "Total bidding activity ... they have been for any complete year since the company has ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... entity to deal with for regulators. , ,In an editorial ... it, I observed that consolidation just like in the ... evolution and is critical for survival: , As a country, ... "revestiture". Revestiture is the industry's modern attempt to circle the ...
... LLC , a software company in Waukesha that sells home ... programs, said on Thursday it has been acquired by a ... it would expand its offerings to manufacturers and retailers by ... and product pictures. Big Hammer operates one of 11 authorized ...
... water main break Thursday at the Milwaukee County Grounds ... 37 companies in the Milwaukee County Research Parks Technology ... businesses in the incubator building were functioning despite the ... in the 137,000-square-foot Technology Innovation Center, said the center ...
Cached Biology Technology:Old bell system merging back together, but it's not the same 2Old bell system merging back together, but it's not the same 3Old bell system merging back together, but it's not the same 4
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... how the bowel lining develops and, in the process, ... , The researchers produced evidence that stem cells are ... a feature of the bowel lining, and believe these ... controversial finding as scientists are still divided on the ... Chin Wee Tan and Professor Tony Burgess from the ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... made concerning the possible inventory of molecules available ... Pizzarello, a research professor at Arizona State University, ... in a blazing fireball over California last year, ... meteorites. These findings suggest a far greater availability ...
... R.I. [Brown University] Although preeclampsia occurs in about ... cases. A report of new research, now in press ... how two distinct risk factors combine to affect the ... life-threatening pregnancy complication. The findings suggest there could be ...
... engineering capabilities that underpin the nuclear weapons stockpile stewardship ... laboratories are "healthy and vibrant," says a new report ... wrote the report found no problems with the quality ... the stockpile. However, the report identifies several issues that, ...
Cached Biology News:ASU scientists strike scientific gold with meteorite 2Study details paired risk factors in preeclampsia 2Study details paired risk factors in preeclampsia 3New report reviews science and engineering quality at national security laboratories 2
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Antibody Diluent for IHC 125 ml...
Biology Products: